Indacaterol for chronic obstructive pulmonary disease (COPD)

Cazzola, Mario; Proietto, Alfio; Matera, Maria Gabriella

doi:10.1358/dot.2010.46.3.1450070

Cited by 28 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with their ability to cross the blood-brain barrier, leading to CNS levels approximately 5% of those seen in plasma (Caccia and Fong 1984). Use of indacaterol can also elicit cough in some users, although when cough does occur, it is mild in severity, transient in nature and duration, and declines with the duration of treatment (Cazzola et al, 2010d).…”

Section: F Side Effects Of ␤ 2 -Adrenergic Receptor Agonistssupporting

confidence: 65%

“…In addition to lipophilicity, potency and intrinsic efficacy have also been shown to be contributing factors in regulating these in vitro time course profiles (Baur et al, 2010). Extensive preclinical studies involving indacaterol have been performed both in vitro and in vivo and have documented that it demonstrates a unique rapid onset of action and a bronchodilating effect that lasts for 24 h (Cazzola et al, 2010d).…”

Section: Ultra-long-acting ␤ 2 -Adrenergic Receptor Agonistsmentioning

confidence: 99%

“…Indacaterol also provided significant and clinically relevant better health-related quality of life. In all studies designed to investigate whether indacaterol has the same tolerability of LABAs already on the market, indacaterol was well tolerated at all doses and with a good overall safety profile (Cazzola et al, 2010d).…”

Section: Ultra-long-acting ␤ 2 -Adrenergic Receptor Agonistsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacology and Therapeutics of Bronchodilators

et al. 2012

View full text Add to dashboard Cite

Section: F Side Effects Of ␤ 2 -Adrenergic Receptor Agonistssupporting

confidence: 65%

Section: Ultra-long-acting ␤ 2 -Adrenergic Receptor Agonistsmentioning

confidence: 99%

Section: Ultra-long-acting ␤ 2 -Adrenergic Receptor Agonistsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacology and Therapeutics of Bronchodilators

et al. 2012

View full text Add to dashboard Cite

“…2) [35]. This drug has an intense intrinsic activity at the level of β 2 -ARs, and its bronchodilating action does not elicit significant tachyphylaxis [34].…”

Section: Indacaterol - Mechanism Of Action and Clinical And Functionamentioning

confidence: 99%

Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium

Pelaia

Maselli²,

Matera³

2014

Pharmacology

View full text Add to dashboard Cite

Bronchodilators are the cornerstone of the treatment of chronic obstructive pulmonary disease (COPD). In particular, the most commonly used drugs are inhaled long-acting agents, including long-acting F₂-adrenergic agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs). The combination of a LABA with a LAMA, i.e. of molecules characterized by different mechanisms of action, results in a synergistic enhancement of their clinical and functional effects. Therefore, this combined treatment can be implemented in a number of cases in which disease control is not adequately achieved by a single active agent such as a LABA or a LAMA. Several LABA/LAMA fixed-dose combinations, mainly made up of newly developed compounds, are currently in advanced phases of experimental evaluation. Within such a context, the aim of this review is to outline the pharmacological basis of dual bronchodilation as well as to discuss the results of the main trials carried out using the drug combination consisting of indacaterol and glycopyrronium, a LABA and a LAMA recently introduced in the treatment of COPD. i 2014 S. Karger AG, Basel

show abstract

“…Indacaterol significantly improved lung function, health status, dyspnoea, rescue medication use, exercise endurance time and rate of exacerbations versus placebo [64,65]. Indacaterol has also demonstrated superior bronchodilation and clinical efficacy compared with the twice-daily LABAs salmeterol [66] and formoterol [67], and is at least as effective in improving lung function and symptoms as tiotropium [68,69].…”

Section: Indacaterolmentioning

confidence: 99%

Addressing unmet needs in the treatment of COPD

Patalano¹,

Banerji²,

D’Andrea³

et al. 2014

European Respiratory Review

View full text Add to dashboard Cite

The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting b 2 -agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patientreported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised. @ERSpublications There is a need to optimise COPD treatment, with the aim of improving patients' lives

show abstract

Indacaterol for chronic obstructive pulmonary disease (COPD)

Cited by 28 publications

References 31 publications

Pharmacology and Therapeutics of Bronchodilators

Pharmacology and Therapeutics of Bronchodilators

Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium

Addressing unmet needs in the treatment of COPD

Contact Info

Product

Resources

About